0000899243-21-035558.txt : 20210910
0000899243-21-035558.hdr.sgml : 20210910
20210910164709
ACCESSION NUMBER: 0000899243-21-035558
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210908
FILED AS OF DATE: 20210910
DATE AS OF CHANGE: 20210910
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Reeve Emma
CENTRAL INDEX KEY: 0001680329
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38560
FILM NUMBER: 211247550
MAIL ADDRESS:
STREET 1: C/O PAREXEL INTERNATIONAL CORPORATION
STREET 2: 195 WEST STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aadi Bioscience, Inc.
CENTRAL INDEX KEY: 0001422142
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 611547850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 17383 SUNSET AVENUE
STREET 2: SUITE A250
CITY: PACIFIC PALISADES
STATE: CA
ZIP: 90272
BUSINESS PHONE: 424-473-8055
MAIL ADDRESS:
STREET 1: 17383 SUNSET AVENUE
STREET 2: SUITE A250
CITY: PACIFIC PALISADES
STATE: CA
ZIP: 90272
FORMER COMPANY:
FORMER CONFORMED NAME: Aerpio Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20170316
FORMER COMPANY:
FORMER CONFORMED NAME: ZETA ACQUISITION CORP II
DATE OF NAME CHANGE: 20071227
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-09-08
0
0001422142
Aadi Bioscience, Inc.
AADI
0001680329
Reeve Emma
C/O AADI BIOSCIENCE, INC.
17383 SUNSET BOULEVARD, SUITE A250
PACIFIC PALISADES
CA
90272
1
0
0
0
Stock option (right to buy)
27.67
2021-09-08
4
A
0
16486
0.00
A
2031-09-08
Common Stock
16486
16486
D
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the Initial Award shall be fully vested on the three year anniversary of the grant date. The grant date is September 8, 2021.
/s/ Lance Thibault, as Attorney-in-Fact
2021-09-10